GMT of the serum SARS-CoV-2 binding antibodies (anti-S, anti S1, and anti-RBD);GMT of the serum SARS-CoV-2 S neutralizing antibodies;Proportion of subjects with four folds increase in serum SARS-CoV-2 binding antibodies (anti-S, anti S1, and anti- RBD);Proportion of subjects with four folds increase in serum SARS-CoV-2 neutralizing antibodies;The percentage and frequency of study subjects reporting adverse events (AE);The percentage and frequency of study subjects reporting local reaction;The percentage and frequency of study subjects reporting systemic events (SAE);The percentage of study subjects reporting systematic reaction

GMT of the serum SARS-CoV-2 binding antibodies (anti-S, anti S1, and anti-RBD);GMT of the serum SARS-CoV-2 S neutralizing antibodies;Proportion of subjects with four folds increase in serum SARS-CoV-2 binding antibodies (anti-S, anti S1, and anti- RBD);Proportion of subjects with four folds increase in serum SARS-CoV-2 neutralizing antibodies;The percentage and frequency of study subjects reporting adverse events (AE);The percentage and frequency of study subjects reporting local reaction;The percentage and frequency of study subjects reporting systemic events (SAE);The percentage of study subjects reporting systematic reaction